Here's the earnings forecast out to 2027 for CSL shares

There could be healthy profit growth in the coming years.

Owners of CSL Ltd (ASX: CSL) shares own a piece of Australia's biggest ASX healthcare share. It's one of the larger global biotechnology businesses, and it plans to become much bigger.

The company has already done well for investors, rising by around 330% over the past decade — plus all of the dividend payments.

If profit rises, the CSL share price could rise in the future. Investors usually value a company based on its current and expected profit.

We're going to look at what profit the broker UBS projects the ASX biotech giant to make in the next few years, starting with FY24.

Two lab workers fist pump each other.

Image source: Getty Images

FY24 reporting soon

We have now entered the August reporting season, during which investors will be able to analyse the performance of various businesses.

CSL plans to report its result just over a week away on 13 August.

For the 2024 financial year, the ASX healthcare share is expected to report it made US$14.7 billion of revenue, US$4.31 billion of earnings before interest and tax (EBIT) and net profit after tax (NPAT) of US$2.99 billion. The company is projected to generate US$6.18 of earnings per share (EPS) and pay an annual dividend per share of US$2.60.

Each of the above numbers would represent an increase of around 10%, with UBS expecting net profit growth of 14%. If CSL can follow this growth up with more profit increases, this could be good news for the share price.

Next, FY25

UBS expects the company to continue growing in FY25 as it recovers from the headwinds of COVID-19.

According to the broker, CSL could generate US$15.7 billion in revenue and US$3.49 billion in net profit in the 2025 financial year. That profit figure would represent a forecast rise of 16.7% year over year.

UBS recently said in a note that collection costs in the plasma space fell during the three months to 31 March 2024, "lending some confidence in the Behring gross margin recovery trajectory through FY25".

The broker is also "incrementally more confident" about the mid-term sales growth outlook for CSL's vaccines.

FY26 projection

UBS has suggested that the financial growth for CSL can continue into FY26.

The broker has projected that CSL's revenue could rise to US$17 billion. This could enable the ASX healthcare share to generate US$4.1 billion of NPAT. Reaching this level of profit in the 2026 financial year would result in the company seeing net profit growth of 18.4% year over year.

And finally, FY27

The 2027 financial year is predicted to be the best year of all, according to UBS.

In FY27, CSL could see US$18.7 billion of revenue, US$6.5 billion of EBIT and US$4.88 billion of NPAT. That profit number would translate into 18.1% year-over-year growth.

If CSL can make that amount of profit, it would equate to an EPS of US$10.08, which could fund an annual dividend per share of US$3.46.

At the current CSL share price, that means it's trading at 20x FY27's estimated earnings. If profit were to keep rising at a double-digit rate after that, then the CSL share price could be an appealing valuation.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »